Physician profile
Charles Petrunin
NPI 1881788099
$960.74
in general payments reported to CMS, 2019-2025
19 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.33 · 2020: $64.56 · 2021: $11.92 · 2022: $110 · 2023: $125 · 2024: $213 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $639 · Education: $71.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.87 |
| Education | $71.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $186.25 | 2022-2025 | |
| Pfizer INC. | $173.65 | 2020-2025 | |
| Janssen Biotech, INC. | $75.84 | 2019-2022 | |
| Abbvie INC. | $60.09 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $59.18 | 2020-2025 | Opdualag |
| Aveo Pharmaceuticals, INC. | $55.00 | 2024-2025 | |
| Genzyme Corporation | $43.53 | 2024-2025 | |
| Kite Pharma, INC. | $42.32 | 2022-2025 | Yescarta |
| Acrotech Biopharma INC. | $34.23 | 2024 | Beleodaq |
| Astellas Pharma US INC | $32.39 | 2024 | Vyloy |
| Puma Biotechnology, INC. | $31.31 | 2019 | |
| Tempus Ai, INC | $30.57 | 2025 | Xt Cdx |
| Daiichi Sankyo INC. | $23.31 | 2023 | Enhertu |
| Glaxosmithkline, LLC. | $21.73 | 2022 | |
| Merck Sharp & Dohme LLC | $21.62 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $20.88 | 2025 | Ogsiveo |
| Verity Pharmaceuticals INC. | $20.69 | 2025 | Trelstar |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2023 | Tazverik, Onivyde |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Petrunin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.